A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
P. Som(Brookhaven National Laboratory), STEPHEN ZABINSKI(Brookhaven National Laboratory), Harold Atkins(University of Ottawa), D.F. Sacker(Brookhaven National Laboratory), D. Bandoypadhyay(Brookhaven National Laboratory), Kosuke Matsui(Kansai Medical University), Z.H. Oster(Brookhaven National Laboratory), Robert MacGregor(Brookhaven National Laboratory), Joanna S. Fowler(Brookhaven National Laboratory), C.N. Wan(Brookhaven National Laboratory), Chyng‐Yann Shiue(Brookhaven National Laboratory), Alfred P. Wolf(Brookhaven National Laboratory), Holly Turner(Brookhaven National Laboratory)
Cited by 503
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
|The Lancet|2016|327
Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow
|Molecular Therapy|2007|277